Literature DB >> 3069193

Antibiotic combinations: should they be tested?

G M Eliopoulos1, C T Eliopoulos.   

Abstract

When antibiotic combinations are used to provide a broader spectrum of antimicrobial activity or in an attempt to prevent the emergence of resistant organisms, it is rarely necessary or practical to perform tests of drug interactions in vitro. In vitro testing of combinations may be useful when combinations are used in an attempt to attain synergistic interactions. In some cases, screening methods can be used as substitutes for formal synergy testing. This paper examines the mechanisms of antibiotic interaction leading to synergism or antagonism, surveys attempts to correlate in vitro observations with efficacy in animal models, and reviews clinical data providing evidence for or against a useful role of synergistic antibiotic interactions in the treatment of human infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069193      PMCID: PMC358039          DOI: 10.1128/CMR.1.2.139

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  174 in total

1.  In vivo and in vitro emergence of simultaneous resistance to both beta-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens.

Authors:  F W Goldstein; L Gutmann; R Williamson; E Collatz; J F Acar
Journal:  Ann Microbiol (Paris)       Date:  1983 May-Jun

2.  A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis.

Authors:  R C Moellering; B E Murray; S C Schoenbaum; J Adler; C B Wennersten
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

3.  Plasmid-mediated resistance to antibiotic synergism in enterococci.

Authors:  D J Krogstad; T R Korfhagen; R C Moellering; C Wennersten; M N Swartz
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

4.  Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients.

Authors:  B S Kramer; R Ramphal; K H Rand
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin.

Authors:  W R Wilson; R L Thompson; C J Wilkowske; J A Washington; E R Giuliani; J E Geraci
Journal:  JAMA       Date:  1981 Jan 23-30       Impact factor: 56.272

6.  Aztreonam therapy in neutropenic patients with cancer.

Authors:  P G Jones; K V Rolston; V Fainstein; L Elting; R S Walters; G P Bodey
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

7.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

8.  Antagonistic effect of penicillin-amikacin combinations against enterococci.

Authors:  C Thauvin; G M Eliopoulos; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis.

Authors:  R J Backes; M S Rouse; N K Henry; J E Geraci; W R Wilson
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

Review 10.  Amdinocillin therapy of experimental animal infections.

Authors:  F M Gordin; M A Sande
Journal:  Am J Med       Date:  1983-08-29       Impact factor: 4.965

View more
  57 in total

1.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Effects of amoxicillin subinhibitory concentrations on the cross-protection developed by pneumococcal antibodies in mouse sepsis caused by an amoxicillin-resistant serotype 6B Streptococcus pneumoniae strain.

Authors:  D Tarragó; L Aguilar; M J Giménez; A Fenoll; J Casal
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

4.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 5.  Aminoglycosides: An Overview.

Authors:  Kevin M Krause; Alisa W Serio; Timothy R Kane; Lynn E Connolly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

6.  Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection.

Authors:  Wan Beom Park; Hong Bin Kim; Nak-Hyun Kim; Jeong Eun Cho; Yoon Jeong Choi; Su Jin Choi; Soo Youn Jun; Chang Kyung Kang; Kyoung-Ho Song; Pyoeng Gyun Choe; Ji-Hwan Bang; Eu Suk Kim; Sang Won Park; Nam-Joong Kim; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

Authors:  E Gradelski; L Valera; D Bonner; J Fung-Tomc
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 9.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.

Authors:  A Cometta; J D Baumgartner; D Lew; W Zimmerli; D Pittet; P Chopart; U Schaad; C Herter; P Eggimann; O Huber
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.